We identified three GALT3-derived peptides that can be recognised by HLA-A2-restricted CTLs, and two of them possessed an ability to induce HLA-A2-restricted and tumour-reactive CTLs in PBMC culture of patients with brain tumours, but not in PBMC culture of healthy donors. The gene discussed is B3GALNT1; the disease is neoplasm.